121 related articles for article (PubMed ID: 6663321)
21. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
22. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
Edwards BS; Hawkins MJ; Borden EC
Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
[TBL] [Abstract][Full Text] [Related]
23. [A phase I study of recombinant interleukin 2 (S6820)].
Takaku F
Gan To Kagaku Ryoho; 1988 Dec; 15(12):3271-6. PubMed ID: 3058043
[TBL] [Abstract][Full Text] [Related]
24. NTP Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CAS No. 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 423():1-336. PubMed ID: 12616288
[TBL] [Abstract][Full Text] [Related]
25. NTP Toxicology and Carcinogenesis Studies of C.I. Direct Blue 218 (CAS No. 28407-37-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Feb; 430():1-280. PubMed ID: 12616301
[TBL] [Abstract][Full Text] [Related]
26. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
27. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.
Robertson MJ; Cameron C; Atkins MB; Gordon MS; Lotze MT; Sherman ML; Ritz J
Clin Cancer Res; 1999 Jan; 5(1):9-16. PubMed ID: 9918197
[TBL] [Abstract][Full Text] [Related]
28. Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity.
Lichtenstein A; Spina C; Berek JS; Jung T; Zighelboim J
Cancer Res; 1988 Oct; 48(20):5853-9. PubMed ID: 3167841
[TBL] [Abstract][Full Text] [Related]
29. Systemic administration of human leukocyte interferon to melanoma patients. I. Effects on natural killer function and cell population.
Golub SH; Dorey F; Hara D; Morton DL; Burk MW
J Natl Cancer Inst; 1982 May; 68(5):703-10. PubMed ID: 6175787
[TBL] [Abstract][Full Text] [Related]
30. NTP Toxicology and Carcinogenesis Studies of p-Nitrobenzoic Acid (CAS No. 62-23-7) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 442():1-306. PubMed ID: 12595921
[TBL] [Abstract][Full Text] [Related]
31. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
32. NTP technical report on the toxicity studies of Riddelliine (CAS No. 23246-96-0) Administered by Gavage to F344 Rats and B6C3F1 Mice.
Chan P
Toxic Rep Ser; 1993 Dec; 27():1-D9. PubMed ID: 12209179
[TBL] [Abstract][Full Text] [Related]
33. A phase I clinical tolerance study of polyadenylic-polyuridylic acid in cancer patients.
Ducret JP; Caillé P; Sancho Garnier H; Amiel JL; Michelson M; Hovanessian AG; Youn JK; Lacour F
J Biol Response Mod; 1985 Apr; 4(2):129-33. PubMed ID: 3998763
[TBL] [Abstract][Full Text] [Related]
34. Correlation between in vitro and systemic effects of native and recombinant interferons-alpha on human natural killer cell cytotoxicity.
Edwards BS; Hawkins MJ; Borden EC
J Biol Response Mod; 1983; 2(5):409-17. PubMed ID: 6644345
[TBL] [Abstract][Full Text] [Related]
35. [Phase-1 study of the tolerance for increasing doses of recombinant human alpha 2 interferon in patients with advanced cancer].
Bretaudeau B; Palangie T; Giralt E; Jouve M; Pouillart P; Falcoff E; Fridman WH; Magdelenat H; Derstepani L; Laurent T
Bull Cancer; 1984; 71(1):40-9. PubMed ID: 6713113
[TBL] [Abstract][Full Text] [Related]
36. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
37. Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN-alpha) in phase I-II trials.
Ernstoff MS; Fusi S; Kirkwood JM
J Biol Response Mod; 1983; 2(6):528-39. PubMed ID: 6363630
[TBL] [Abstract][Full Text] [Related]
38. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
39. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
Giaccone G; Punt CJ; Ando Y; Ruijter R; Nishi N; Peters M; von Blomberg BM; Scheper RJ; van der Vliet HJ; van den Eertwegh AJ; Roelvink M; Beijnen J; Zwierzina H; Pinedo HM
Clin Cancer Res; 2002 Dec; 8(12):3702-9. PubMed ID: 12473579
[TBL] [Abstract][Full Text] [Related]
40. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
